Dr. Janik Kaufmann, technical sales specialist Oligonucleotides, Hongene Biotech, looks at why chemoenzymatic technologies are moving into the spotlight.
The oligonucleotide therapeutics industry is entering a new phase of growth. Following the clinical and commercial success of the first wave of antisense oligonucleotides (ASOs), siRNAs, and emerging gene-editing modalities primarily addressing rare diseases, market projections suggest that several upcoming siRNA therapeutics targeting highly prevalent diseases such as cardiovascular, metabolic, and liver diseases could reach patient populations far beyond the rare disease indications. As a result, manufacturing demand is expected to increase substantially over the coming decade making production capacity, scalability, and cost of goods decisive factors for commercial success.